Biolidics Limited (SGX:8YY)

Market Cap	27.99M
Revenue (ttm)	858.00K
Net Income (ttm)	-3.43M
Shares Out	1.56B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	590,000
Average Volume	1,187,015
Open	0.0200
Previous Close	0.0200
Day's Range	0.0180 - 0.0200
52-Week Range	0.0080 - 0.0330
Beta	0.69
RSI	39.49
Earnings Date	May 2, 2025

About Biolidics

Biolidics Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions in Japan, Hong Kong, Thailand, Malaysia, and the United States. It operates through Cancer, Infectious Diseases, and Laboratory Services segments. The company offers ClearCell FX1 System that includes Streck Cell-free DNA BCT and EDTA tubes, a fully automated device for cell retrieval that can separate wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood; and CTChip FR1 biochip that isol...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2009
• Employees: 15
• Stock Exchange: Singapore Exchange - Catalist
• Ticker Symbol: 8YY

Financial Performance

In 2024, Biolidics's revenue was 858,000, an increase of 176.77% compared to the previous year's 310,000. Losses were -3.43 million, 38.0% more than in 2023.